BMC Elections Conclude: High-stakes showdown between Fadnavis and Thackeray in Mumbai

'That’s good news, but we haven’t got intimation yet': NSE CEO on SEBI IPO clearance

MSME schemes set for major overhaul as NITI Aayog pushes convergence roadmap to boost efficiency, outreach

Federal Bank Q3 FY26 Results Preview: Lender likely to recover interest income, loan growth pegged at nearly 9%

Maha overtakes Delhi in e-bus sales, TN races past Guj: 5 key trends in 2025 Vahan data

India-EU FTA: Negotiations near completion ahead of January 27 summit; EU leaders to attend Republic Day

India's chemical sector facing risk from China overcapacity, high crude prices and weak global demand: Nuvama

Govt launches IndiaAI challenge to build AI tools for auditing, financial reporting oversight — Know details

L&T Technology Services Q3FY26: Revenue up 10.2%, margins improve sequentially

What’s new in Bajaj Chetak C25: 9 key highlights you should know

While Indian markets are soaring to an extreme level today, there was no love for the pharma-major Sun Pharmaceuticals Industries. There was massive bloodbath in the company and the shares crashed by 11.39% in an early trade today with an intraday low of Rs 441.95. Currently, the stock is trading at Rs 458.00 per piece lower by 34.30 or 6.97% at around 1049 hours.
Such decline in shares comes despite the company announcing that Sun Pharma has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL. The generic version is therapeutic equivalent to Organon’s Ganirelix Acetate Injection, 250 mcg/0.5 mL. 
But no, this is not the reason for the drop in Sun Pharma shares.
The reason behind the Sun Pharma share price plunge may well be the market watchdog. Yes, it can be blamed on market regulator Sebi, which is planning to re-open an old investigation in the company, after a 150-page letter was sent by a whistleblower. 
According to a PTI report,  sources stated that, SEBI plans to reopen the investigation into the insider trading case against the company and its promoters that was settled through the consent mechanism.
Reportedly, Macquarie in its note raised several questions about corporate governance practices by the company. The note points to alleged connections with tainted entities like Ketan Parekh and Dharmesh Doshi, and the conflict of interest with regards to Sudhir Valia, a whole-time director of Sun Pharma who is also the brother-in-law of promoter Dilip Shanghvi.
Further, the note talks about real estate guarantees given to Suraksha Realty, apart from seeking clarification as to why a little known London-based firm Jermyn Capital was selected to manage Sun Pharma's $275 million foreign convertible bond issue back in 2004-07. Jermyn's Indian arm has links with Parekh and Doshi, who are the two traders who have come under scrutiny for the market crash of 2002.
Watch Zee Business Tweet video here:
<blockquote data-lang="en"><a href="https://twitter.com/hashtag/ZBizHeadlines?src=hash&amp;ref_src=twsrc%5Etfw">#ZBizHeadlines</a> | ट्रेड वॉर की टेंशन घटने से मेटल शेयरों की चमक बढ़ी...टाटा स्टील, हिंडाल्को और वेंदाता में 4% तक की तेजी। देखिए बाजार से जुड़ी बड़ी खबरें। <a href="https://t.co/Ldhij9uUlm">pic.twitter.com/Ldhij9uUlm</a>
— Zee Business (@ZeeBusiness) <a href="https://twitter.com/ZeeBusiness/status/1069485049383403520?ref_src=twsrc%5Etfw">December 3, 2018</a></blockquote>
<script async="" src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Hence, today Sun Pharma has made its investor quite poor, on the back of panic selling. So should you invest going ahead? 
UBS in a Bloomberg Quint report said,  "Whistle-blower allegations are valuation dampener at the minimum. Negatively impacts Management bandwidth at a time when key brands are getting launched. Expect stock to react negatively to the whistle-blower allegations."
However, as far as investors are concerned, UBS has Maintained ‘Buy’ with a price target of Rs 690 on the company. That should answer their most important question.

While Indian markets are soaring to an extreme level today, there was no love for the pharma-major Sun Pharmaceuticals Industries. There was massive bloodbath in the company and the shares crashed by 11.39% in an early trade today with an intraday low of Rs 441.95. Currently, the stock is trading at Rs 458.00 per piece lower by 34.30 or 6.97% at around 1049 hours.Such decline in shares comes despite the company announcing that Sun Pharma has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL. The generic version is therapeutic equivalent to Organon’s Ganirelix Acetate Injection, 250 mcg/0.5 mL. But no, this is not the reason for the drop in Sun Pharma shares.The reason behind the Sun Pharma share price plunge may well be the market watchdog. Yes, it can be blamed on market regulator Sebi, which is planning to re-open an old investigation in the company, after a 150-page letter was sent by a whistleblower. According to a PTI report,  sources stated that, SEBI plans to reopen the investigation into the insider trading case against the company and its promoters that was settled through the consent mechanism.Reportedly, Macquarie in its note raised several questions about corporate governance practices by the company. The note points to alleged connections with tainted entities like Ketan Parekh and Dharmesh Doshi, and the conflict of interest with regards to Sudhir Valia, a whole-time director of Sun Pharma who is also the brother-in-law of promoter Dilip Shanghvi.Further, the note talks about real estate guarantees given to Suraksha Realty, apart from seeking clarification as to why a little known London-based firm Jermyn Capital was selected to manage Sun Pharma's $275 million foreign convertible bond issue back in 2004-07. Jermyn's Indian arm has links with Parekh and Doshi, who are the two traders who have come under scrutiny for the market crash of 2002.Watch Zee Business Tweet video here:#ZBizHeadlines | ट्रेड वॉर की टेंशन घटने से मेटल शेयरों की चमक बढ़ी...टाटा स्टील, हिंडाल्को और वेंदाता में 4% तक की तेजी। देखिए बाजार से जुड़ी बड़ी खबरें। pic.twitter.com/Ldhij9uUlm— Zee Business (@ZeeBusiness) December 3, 2018Hence, today Sun Pharma has made its investor quite poor, on the back of panic selling. So should you invest going ahead? UBS in a Bloomberg Quint report said,  "Whistle-blower allegations are valuation dampener at the minimum. Negatively impacts Management bandwidth at a time when key brands are getting launched. Expect stock to react negatively to the whistle-blower allegations."However, as far as investors are concerned, UBS has Maintained ‘Buy’ with a price target of Rs 690 on the company. That should answer their most important question.

There was massive bloodbath in the company and the shares crashed by 11.39% in an early trade today with an intraday low of Rs 441.95.

What went wrong with Sun Pharma shares? Shocks investors, plunges 11% as Dilip Shanghvi under scanner; should you invest? 

news-what-went-wrong-with-sun-pharma-shares-shocks-investors-plunges-11-as-dilip-shanghvi-under-scanner-should-you-invest-73934

While Indian markets are soaring to an extreme level today, there was no love for the pharma-major Sun Pharmaceuticals Industries. There was massive bloodbath in the company and the shares crashed by 11.39% in an early trade today with an intraday low of Rs 441.95. Currently, the stock is trading at Rs 458.00 per piece lower by 34.30 or 6.97% at around 1049 hours. Such decline in shares comes despite the company announcing that Sun Pharma has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL. The generic version is therapeutic equivalent to Organon’s Ganirelix Acetate Injection, 250 mcg/0.5 mL.  But no, this is not the reason for the drop in Sun Pharma shares. The reason behind the Sun Pharma share price plunge may well be the market watchdog. Yes, it can be blamed on market regulator Sebi, which is planning to re-open an old investigation in the company, after a 150-page letter was sent by a whistleblower.  According to a PTI report,  sources stated that, SEBI plans to reopen the investigation into the insider trading case against the company and its promoters that was settled through the consent mechanism. Reportedly, Macquarie in its note raised several questions about corporate governance practices by the company. The note points to alleged connections with tainted entities like Ketan Parekh and Dharmesh Doshi, and the conflict of interest with regards to Sudhir Valia, a whole-time director of Sun Pharma who is also the brother-in-law of promoter Dilip Shanghvi. Further, the note talks about real estate guarantees given to Suraksha Realty, apart from seeking clarification as to why a little known London-based firm Jermyn Capital was selected to manage Sun Pharmas $275 million foreign convertible bond issue back in 2004-07. Jermyns Indian arm has links with Parekh and Doshi, who are the two traders who have come under scrutiny for the market crash of 2002. Watch Zee Business Tweet video here: #ZBizHeadlines | ट्रेड वॉर की टेंशन घटने से मेटल शेयरों की चमक बढ़ी...टाटा स्टील, हिंडाल्को और वेंदाता में 4% तक की तेजी। देखिए बाजार से जुड़ी बड़ी खबरें। pic.twitter.com/Ldhij9uUlm — Zee Business (@ZeeBusiness) December 3, 2018 Hence, today Sun Pharma has made its investor quite poor, on the back of panic selling. So should you invest going ahead?  UBS in a Bloomberg Quint report said,  Whistle-blower allegations are valuation dampener at the minimum. Negatively impacts Management bandwidth at a time when key brands are getting launched. Expect stock to react negatively to the whistle-blower allegations. However, as far as investors are concerned, UBS has Maintained ‘Buy’ with a price target of Rs 690 on the company. That should answer their most important question.

There was massive bloodbath in the company and the shares crashed by 11.39% in an early trade today with an intraday low of Rs 441.95.